데이터 자료를 살펴보세요

[Syngeneic colorectal CT26 model (#578600), tumor growth over time (Day). Murine colorectal CT26 cells, at 5 x 10⁵ cells/mouse, were subcutaneously implanted into female BALB/c mice. Treatment was initiated on Day 1 upon randomization when the mean tumor volume reached 40-80 mm³. Murine anti-VEGF and CTLA-4 antibodies were intraperitoneally administered twice per week (top left panel), followed by TILs analysis on Day 21.The percentage of live and murine CD45 positive cell populations are plotted (top right panel).The percentage of murine natural killer (NK) cells, myeloid-derived suppressor cells (MDSC), and CD8 positive T-cells are plotted with respect to live CD45 positive cells for each group.(*): Indicates a significant (p < 0.05) reduction in the mean tumor volume compared to vehicle control as determined by two-way ANOVA followed by Bonferroni correction. Significant difference (**p < 0.01 and **p < 0.001) in the population of immune cells compared to vehicle control as determined by one-way ANOVA followed by Dunnett’s test. Error bars are SEM values.

[Xenograft model of human Duke’s type B colorectal carcinoma SW480 (#580150), tumor growth over time (Day). Female nu/nu mice, 6 weeks of age, were subcutaneously (SC) implanted with viable human colorectal carcinoma SW480 cells at 5 x 10⁶ cells/mouse (0.2 mL/animal with 50% Matrigel). Treatment was initiated on Day 1 upon randomization when the mean tumor volume reached 100-150 mm3. Paclitaxel at 25 mg/kg was intravenously (IV) administered once every other day for a total of 5 doses (QOD x 5).Fluorouracil (5-FU) at 75 mg/kg and Bevacizumab at 5 mg/kg were each intraperitoneally (IP) administered with respect to once (QWK) and twice (BIW) per week for 3 consecutive weeks. A combination therapy of 5-FU and Bevacizumab was assessed to compare the effect with monotherapies. Irinotecan at 75 mg/kg IP administered QWK x 3 weeks. Tumor growth, tumor volume by length x (width)² x 0.5, was measured thrice per week from Day 1 (treatment initiation) till the study end date. Error bars are SEM values.(*): Indicates a significant (p < 0.05) reduction in mean tumor volume compared to vehicle control as determined by two-way ANOVA followed by Bonferroni correction. Error bars are SEM values.]

[Orthotopic model of human triple-negative breast carcinoma MDA-MB-231. Female NPG mice, 6 weeks of age, were orthotopically implanted with viable human TNBC MDA-MB-231 cells at the selected target cell density into the mammary fat pad at 0.05 mL/animal. Tumor growth was measured by IVIS and caliper twice per week throughout the study progression. Both the caliper and IVIS versions with MDA-MB-231-Luc (luciferase labeled) cells are available (#580022). Representative luciferase signal in the bottom left panel throughout the course of the study. Multiple organ metastases are found, as shown in the bottom right panel. The xenograft (#580020) and orthotopic (#580021) models with the parental MDA-MB-231 (unlabeled cells) are also available for selection.]

[Patient-derived xenograft model with colorectal carcinoma, tumor growth over time (Day). Female ASID, NPG, and NOD/SCID mice, 8 weeks of age, were subcutaneously (SC) implanted with tumor fragments (passage number 3) obtained from an age 45 male patient with adenocarcinoma colorectal cancer at the upper rectum, stage IV A, poorly differentiated. Tumor growth, tumor volume by length x (width)2 x 0.5, was measured twice per week during the study progression.]